Ranbaxy Laboratories Ltd today reported a consolidated loss of Rs 761 crore for the first quarter ended March 31, 2009.
The company had reported a profit of Rs 85.8 crore in the same quarter last year.
Sales dipped by 4 per cent to Rs 1,558.4 crore in the first quarter of the current year compared to Rs 1,623.1 crore in the same period last year, the company said in statement.
In the first quarter, the company's sales in North America declined by 7 per cent to Rs 404 crore compared to Rs 435.1 crore in the same quarter last year.
Ranbaxy also reported a 14 per cent decline in its sales in Europe at 283.1 crore for the March quarter compared to Rs 329 crore in the same quarter last year.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app